PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025 WILMINGTON ...

Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, developmen ...

NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical- stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast wil ...

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour   BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase degraders demonstrate potential to address both enzymatic and scaffolding functions and promote tumor regression in brain and small cell lung cancer models  SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical- ...

Kymera Therapeutics (KYMR) Conference February 06, 2025 10:00 AM ET Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Conference Call Participants Michael Schmidt - Senior Managing Director & Equity Research Analyst - Biotechnology Michael Schmidt Michael Schmidt, senior biotic analyst with Guggenheim, and I'd like to welcome, Nelo Manolfi, the founder, president, and CEO of Chimera to this next fireside chat. Nelo, welcome and thanks for joining us. Nello Mainolfi Thanks, Michael, ...

C4 Therapeutics (CCCC) FY Conference January 09, 2023 01:30 PM ET Speaker0 We'll get started. I'm Eric Joseph, Senior Biotech Analyst with JPMorgan. Our next presenting company is C4 Therapeutics, and presenting on behalf of the company is CEO, Andrew Hirsch. We'll be doing Q and A after the presentation in the room. And for those viewing on the digital conference book, feel free to submit questions via the portal. So with that, Andrew? Speaker1 Thanks, Eric, and thanks for JPMorgan for having us here today ...